Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Arrowhead Pharmaceuticals kazanç ve gelirinin sırasıyla yıllık 28.2% ve 46.1% oranında artması tahmin edilirken, EPS'nin yıllık 29.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

28.2%

Kazanç büyüme oranı

29.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	37.0%
Gelir büyüme oranı	46.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0HI3 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2027	491	-327	-495	-73	6
9/30/2026	240	-459	-546	-311	12
9/30/2025	151	-497	-444	-338	16
9/30/2024	62	-535	-617	-479	16
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	152	157	N/A
3/31/2019	95	10	130	132	N/A
12/31/2018	47	-29	134	136	N/A
9/30/2018	16	-54	-49	-47	N/A
6/30/2018	14	-54	-55	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A
9/30/2014	0	-59	N/A	-35	N/A
6/30/2014	0	-50	N/A	-30	N/A
3/31/2014	0	-44	N/A	-25	N/A
12/31/2013	0	-37	N/A	-22	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0HI3 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0HI3 şirketinin gelirinin (yıllık 46.1% ) UK pazarından (yıllık 3.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0HI3 şirketinin gelirinin (yıllık 46.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0HI3 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Arrowhead Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Recent updates

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 23% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Chief Financial Officer recently sold US$1.4m worth of stock

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 27% overvalued after recent price rise

First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023)

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

New major risk - Financial position

New major risk - Financial position

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022)

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Chief Medical Officer recently sold US$567k worth of stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Insider selling

Chief Financial Officer recently sold US$543k worth of stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022)

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Independent Director recently sold US$291k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Chairman of the Board recently sold US$326k worth of stock

Chief Commercial Officer James Hassard has left the company

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020)

Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Chief Commercial Officer recently sold US$323k worth of stock

Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020)

Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Chairman of the Board recently sold US$100k worth of stock

First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020)